Cancer-related fatigue and influencing factors analysis in lymphoma patients receiving chemotherapy

Objective Cancer-related Fatigue (CRF) in patients with tumors or tumor treatment process include the subjective feeling of tired, depression, cognitive decline, loss of interest, disability in the original job. These symptoms cannot be relieved after a rest, which seriously affect the daily function, social activities, physical and mental health and quality of life. The objective of this study is to describe the status of Cancer-related fatigue in lymphoma patients receiving chemotherapy, and to explore its influencing factors, so as to provide evidence for the development of effective nursing interventions. Methods A total of 128 lymphoma patients receiving chemotherapy in our hospital from March 2015 to March 2018 by convenience sampling were enrolled into this study. The patients were investigated by general data questionnaire and Piper Fatigue Scale. Variance analysis and Spearman correlation analysis were used in the univariate analysis and logistic regression analysis in the multivariate analysis. Results The score of overall fatigue in 128 research objects was 5.32±2.19, which was at a moderate level. A total of 103 patients were with cancer-related fatigue, with the incidence of 80.5%. Emotional fatigue level was (7.37±3.26) points, which was in a severe fatigue level; the sensory dimension score was (5.48±2.11) points; behavior/severity dimension scored average (5.12±1.97) points, which was the lowest; cognitive/emotional dimension score was (5.87±2.32). Logistic multivariate analysis showed that gender (OR=3.225), times of chemotherapy (OR=2.883) and Ann Arbor staging (OR=3.003) were statistically significant among all the factors that influenced the patients receiving chemotherapy (P<0.05). Conclusion The lymphoma patients receiving chemotherapy are usually with a moderate to severe level cancer-related fatigue, and the incidence is high. The targeted care is suggested to perform among the male patients and the patients with chemotherapy over 10 times or with Ann Arbor stage Ⅲ/Ⅳ to relieve the current state of fatigue.